Search results for Lirilumab

Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade, ProteoGenix, PX-TA1297

Description of Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade General information on Anti-KIRD2 subgroup[Homo sapiens] (Lirilumab) Monoclonal Antibody Lirilumab has been investigated for the treatment of Leukemia, Cancer, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia.

Lirilumab, Abbexa, abx831254

Lirilumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting KIRD2 subgroup, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lirilumab has been used in trials studying the treatment of Leukemia, CANCER, NOS, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia, among others.

Lirilumab ELISA Kit, ProteoGenix, KPTX233

Description of Lirilumab ELISA Kit The Structure of Lirilumab ELISA Kit Lirilumab ELISA Kit is a highly sensitive and specific enzyme-linked immunosorbent assay (ELISA) kit designed for the quantitative measurement of Lirilumab in various biological samples. Lirilumab is a human monoclonal antibody that targets the inhibitory killer cell immunoglobulin-like receptor (KIR) on natural killer (NK) cells. The kit is composed of several components including a microplate coated with a specific antibody against Lirilumab, a detection antibody labeled with an enzyme, and a substrate solution. The microplate is divided into several wells, each of which is coated with the capture antibody. When a sample containing Lirilumab is added to the wells, the antibody binds to the Lirilumab, forming a sandwich complex. The detection antibody, which is specific for a different epitope on Lirilumab, is then added and binds to the Lirilumab in the sandwich complex. The enzyme-labeled detection antibody allows for the quantification of Lirilumab through a colorimetric reaction. The Activity of Lirilumab ELISA Kit Lirilumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Lirilumab in various biological samples. It has a detection range of 0.1-10 ng/mL and a sensitivity of 0.05 ng/mL, making it a highly accurate and reliable method for measuring Lirilumab levels. The kit is designed to specifically detect Lirilumab and does not cross-react with other related antibodies, ensuring the accuracy of the results. The enzyme-labeled detection antibody provides a highly sensitive and specific signal, allowing for the accurate quantification of Lirilumab even in low concentrations. The Application of Lirilumab ELISA Kit Lirilumab ELISA Kit has a wide range of applications in both research and clinical settings. It can be used for the detection and quantification of Lirilumab in various biological samples, including serum, plasma, and cell culture supernatants. In research, the kit can be used to study the expression and activity of Lirilumab in different disease states. It can also be used to investigate the role of Lirilumab in the immune response and its potential as a therapeutic target. In a clinical setting, Lirilumab ELISA Kit can be used for the monitoring of Lirilumab levels in patients receiving Lirilumab therapy. It can also aid in the diagnosis and prognosis of diseases where Lirilumab is involved, such as cancer and autoimmune disorders. The Role of Lirilumab as a Therapeutic Target Lirilumab is a promising therapeutic target in the treatment of various diseases, especially cancer. It works by blocking the inhibitory KIR on NK cells, allowing for the activation and proliferation of these immune cells. This leads to enhanced anti-tumor activity and can potentially improve the response to other cancer therapies. The use of Lirilumab ELISA Kit in the monitoring of Lirilumab levels in patients undergoing Lirilumab therapy can provide valuable information on the efficacy of the treatment and help guide treatment decisions. In conclusion, Lirilumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Lirilumab, a promising therapeutic target in the treatment of various diseases. Its accurate and reliable results make it a valuable tool for both research and clinical applications.

Lirilumab ELISA Kit, Abbexa, abx395122

Lirilumab ELISA Kit is a quantitative ELISA kit for detection of Lirilumab.Lirilumab (IPH2102/BMS-986015/BMS-986015-01) is a fully human monoclonal antibody (mAb) that is designed to block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb. A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017. It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned. On 22 May 2018, a clinical trial for Bladder Cancer was started by PrECOG LLC.

Lirilumab Biosimilar - Research Grade, ichor.bio, ICH5167

Detects human KIR2DL1

Research Grade Lirilumab (HW759016), abinScience, HW759016